Filtered By:
Cancer: Leukemia
Management: Healthcare Costs
This page shows you your search results in order of date.
Order by Relevance | Date
Total 49 results found since Jan 2013.
Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database
This study characterized the magnitude of this burden following initial treatment with standard or less intensive therapies (hypomethylating agents [HMAs]) and throughout different treatment phases post-remission. The Surveillance, Epidemiology, and End Results (SEER) cancer registry (2007-2016) linked with Medicare beneficiary claims (2007-2015) was analyzed. Patients were ≥ 65 years old with AML who initiated chemotherapy or HMAs and achieved remission. Outcomes included baseline characteristics, treatment patterns, clinical outcomes, healthcare resource utilization (HRU), and costs (2019 United States dollar). Economi...
Source: Cell Research - August 10, 2023 Category: Cytology Authors: Andrew M Brunner David Huggar Ronda Copher Zheng-Yi Zhou Miriam L Zichlin Annika Anderson Nathaniel Downes Ali McBride Source Type: research
Economic Impact of Transformation to Acute Myeloid Leukemia Among Actively Managed Patients with Higher-Risk Myelodysplastic Syndromes in the United States
CONCLUSIONS: Patients with higher-risk MDS whose disease transformed to AML incurred significantly higher healthcare costs compared to those whose disease did not transform, highlighting the important need for treatments that prevent or delay transformation.PMID:36422807 | DOI:10.1007/s12325-022-02370-4
Source: Adv Data - November 24, 2022 Category: Epidemiology Authors: Vamsi Kota Augustina Ogbonnaya Eileen Farrelly Bridgette Kanz Schroader Aditya Raju Fjoralba Kristo Mehul Dalal Source Type: research
Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain
CONCLUSIONS: Venetoclax in combination with obinutuzumab is an efficient and dominant alternative for treating previously untreated patients with chronic lymphocytic leukaemia compared to the available alternatives and from the perspective of the Spanish National Health System.PMID:36183205
Source: Farmacia Hospitalaria - October 2, 2022 Category: Drugs & Pharmacology Authors: Estela Moreno-Mart ínez Javier De la Serna-Torroba Vicente Escudero-Vilaplana Jos é Ángel Hernández-Rivas Marina S ánchez-Cuervo Raquel S ánchez-Hernández Source Type: research
